Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform^®) for the treatment of asthma

References

• Bateman ED Hurd SS Barnes PJ Global strategy for asthma management and prevention: GINA executive summary Eur Respir J 2008 31 143 178 18166595
   PubMed Web of Science ®Google Scholar
• National Heart Lung and Blood Institute, National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Rockville (MD) National Asthma Education and Prevention Program, National Heart Lung and Blood Institute 2007
   Google Scholar
• Ducharme FM Ni Chroinin M Greenstone I Lasserson TJ Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children Cochrane Database Syst Rev 2010 CD005535 20464739
   PubMed Web of Science ®Google Scholar
• Ducharme FM Ni Chroinin M Greenstone I Lasserson TJ Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma Cochrane Database Syst Rev 2010 CD005533 20393943
   PubMed Web of Science ®Google Scholar
• Chowdhury BA Dal Pan G The FDA and safe use of long-acting beta-agonists in the treatment of asthma N Engl J Med 2010 362 1169 1171 20181964
   PubMed Web of Science ®Google Scholar
• Tamm M Richards DH Beghe B Fabbri L Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice Respir Med 2012 106 Suppl 1 S9 S19 23273165
   PubMed Web of Science ®Google Scholar
• Barnes PJ Scientific rationale for using a single inhaler for asthma control Eur Respir J 2007 29 587 595 17329493
   PubMed Web of Science ®Google Scholar
• Bousquet J Winchester C Papi A Inhaled corticosteroid/long-acting β2-agonist combination therapy for asthma: attitudes of specialists in Europe Int Arch Allergy Immunol 2012 157 303 310 22056555
   PubMed Web of Science ®Google Scholar
• Shapiro G Lumry W Wolfe J Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma Am J Respir Crit Care Med 2000 161 527 534 10673196
   PubMed Web of Science ®Google Scholar
• Weinstein SF Corren J Murphy K Nolte H White M Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids Allergy Asthma Proc 2010 31 280 289 20687982
   PubMed Web of Science ®Google Scholar
• Edwards SJ Gruffydd-Jones K Ryan DP Systematic review and meta-analysis of budesonide/formoterol in a single inhaler Curr Med Res Opin 2007 23 1809 1820 17597557
   PubMed Web of Science ®Google Scholar
• Noonan M Rosenwasser LJ Martin P O’Brien CD O’Dowd L Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial Drugs 2006 66 2235 2254 17137405
   PubMed Web of Science ®Google Scholar
• Papi A Paggiaro PL Nicolini G Vignola AM Fabbri LM Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma Eur Respir J 2007 29 682 689 17107988
   PubMed Web of Science ®Google Scholar
• Luijk B Kempsford RD Wright AM Zanen P Lammers JW Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction Eur Respir J 2004 23 559 564 15083754
   PubMed Web of Science ®Google Scholar
• Adams NP Bestall JC Jones P Lasserson TJ Griffiths B Cates CJ Fluticasone at different doses for chronic asthma in adults and children Cochrane Database Syst Rev 2008 CD003534 18843646
   PubMed Web of Science ®Google Scholar
• Bousquet J Guenole E Duvauchelle T Vicaut E Lefrancois G A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients Respiration 2005 72 Suppl 1 13 19 15915008
   PubMed Web of Science ®Google Scholar
• Busse W Levine B Andriano K Lavecchia C Yegen U Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study Clin Ther 2004 26 1587 1598 15598475
   PubMed Web of Science ®Google Scholar
• Bartow RA Brogden RN Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma Drugs 1998 55 303 322 9506248
   PubMed Web of Science ®Google Scholar
• Andersson O Cassel TN Grönneberg R Brönnegård M Stierna P Nord M In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma J Allergy Clin Immunol 1999 103 595 600 10200007
   PubMed Web of Science ®Google Scholar
• Berger WE Ford LB Mahr T Efficacy and safety of fluticasone propionate 250 microg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids Ann Allergy Asthma Immunol 2002 89 393 399 12392384
   PubMed Web of Science ®Google Scholar
• Sovijärvi AR Haahtela T Ekroos HJ Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment Thorax 2003 58 500 504 12775860
   PubMed Web of Science ®Google Scholar
• Crim C Pierre LN Daley-Yates PT A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate Clin Ther 2001 23 1339 1354 11589253
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT Parkins DA Systemic bioavailability of hydrofluoroalkane formulations containing fluticasone propionate and salmeterol Br J Clin Pharmacol 2011 72 353 354 author reply 5–6 21453299
   PubMed Web of Science ®Google Scholar
• Dissanayake S Grothe B Kaiser K Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma Respir Med 2012 106 Suppl 1 S20 S28 23273163
   PubMed Web of Science ®Google Scholar
• Pertseva T Dissanayake S Kaiser K Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial Curr Med Res Opin 2013 29 1357 69 23865726
   PubMed Web of Science ®Google Scholar
• Corren J Mansfield LE Pertseva T Blahzko V Kaiser K Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma Respir Med 2013 107 180 195 23273405
   PubMed Web of Science ®Google Scholar
• Nathan RA D’Urzo A Blazhko V Kaiser K Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial BMC Pulm Med 2012 12 67 23078148
   PubMed Web of Science ®Google Scholar
• Pearlman DS LaForce CF Kaiser K Fluticasone/formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma Clin Ther 2013 35 950 966 23870606
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A Pulka G Dymek A Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler Respir Med 2011 105 674 682 21196104
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A van Noord J Schröder-Babo W McAulay K McIver T Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial Curr Med Res Opin 2013 29 579 588 23368897
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A Dymek A McAulay K Mansikka H Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study BMC Pulm Med 2011 11 28 21605396
   PubMed Web of Science ®Google Scholar
• Aalbers R Brusselle G McIver T Grothe B Bodzenta-Lukaszyk A Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study Adv Ther 2012 29 958 69 23081745
   PubMed Web of Science ®Google Scholar
• Cukier A Jacob CM Rosario Filho NA Fluticasone/formoterol dry powder versus budesonide/formoterol in adults and adolescents with uncontrolled or partly controlled asthma Respir Med 2013 107 1330 1338 23849625
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A Buhl R Balint B Lomax M Spooner K Dissanayake S Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety J Asthma 2012 49 1060 1070 23102189
   PubMedGoogle Scholar
• Mansur AH Kaiser K Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma J Aerosol Med Pulm Drug Deliv 2013 26 190 199 23098325
   PubMed Web of Science ®Google Scholar
• ZuWallack R Adelglass J Clifford DP Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma Chest 2000 118 303 312 10936117
   PubMed Web of Science ®Google Scholar
• Nelson HS Weiss ST Bleecker ER Yancey SW Dorinsky PM The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol Chest 2006 129 15 26 16424409
   PubMed Web of Science ®Google Scholar
• Bateman E Nelson H Bousquet J Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events Ann Intern Med 2008 149 33 42 18523132
   PubMed Web of Science ®Google Scholar
• Suissa S Ariel A US Food and Drug Administration-mandated trials of long-acting beta-agonists safety in asthma: will we know the answer? Chest 2013 143 1208 1213 23392216
   PubMed Web of Science ®Google Scholar
• Cazzola M Matera MG Donner CF Inhaled β2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease Drugs 2005 65 1595 1610 16060696
   PubMed Web of Science ®Google Scholar
• Mundipharma International Flutiform (fluticasone propionate/formoterol) [prescribing information] Cambridge, UK Mundipharma International 2012
   Google Scholar
• McKeage K Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma Drugs 2013 73 195 206 23397367
   PubMed Web of Science ®Google Scholar
• O’Byrne PM Bleecker ER Bateman ED Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Eur Respir J 2014 43 773 782 24136330
   PubMed Web of Science ®Google Scholar
• Claxton AJ Cramer J Pierce C A systematic review of the associations between dose regimens and medication compliance Clin Ther 2001 23 1296 1310 11558866
   PubMed Web of Science ®Google Scholar
• Patel M Pilcher J Beasley R Combination ICS/fast-onset LABA inhaler as maintenance and reliever therapy: the future for uncontrolled adult asthma? Expert Rev Respir Med 2013 7 451 454 24138688
   PubMed Web of Science ®Google Scholar
• Hozawa S Terada M Hozawa M Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy Pulm Pharmacol Ther 2014 27 190 196 24388868
   PubMed Web of Science ®Google Scholar